HD-OPM Archive
Hashtags

#statinselderly

12 posts

PREVENTABLE: 20,000-person trial of atorvastatin 40 mg to prevent dementia over age 75

Jun 23, 2025 · Louis Nervegna ♥ 16 · 💬 5 Statins

Louis describes the ongoing PREVENTABLE trial, which randomizes about 20,000 community-dwelling adults aged 75+ to atorvastatin 40 mg or placebo to test whether statins prevent dementia. Atorvastatin was chosen because it is lipophilic and crosses the blood-brain barrier; the trial began in 2020 and is still recruiting.

STREAM: why 'noninferior' does not make stopping statins at age 70 safe

Nov 15, 2026 · Louis Nervegna ♥ 4 · 💬 11 Statins

Louis shares a cardiologist's video commentary on the STREAM randomized trial of stopping statins after age 70. The commentary stresses that the stop group had roughly 38% more events in relative terms (12.7% vs 9.2%), that noninferiority only means the difference fell within a preset margin, and that the safety board advised discussing restarting. Stopping can be appropriate based on frailty or side effects, but not simply because of age.

Older veterans starting statins were less likely to develop frailty

Jun 10, 2026 · Louis Nervegna ♥ 13 · 💬 3 ↩ 1 Statins

Louis shares a large observational study in the European Heart Journal where older US veterans who initiated statins had significantly lower frailty risk over time. Authors suggest anti-inflammatory effects may slow functional decline but emphasize randomized trials are needed.

New statin use linked to less frailty in older veterans; STAREE will test it

Jun 10, 2026 · Louis Nervegna ♥ 5 · 💬 1 Statins

Louis shares the observational VA/Mass General Brigham study (JACC) reporting that older US veterans starting statins developed less frailty over time. He notes two large randomized trials, PREVENTABLE and STAREE, are testing statins in the elderly and tracking frailty, with STAREE expected to report within months.

Stopping statins after 70 raised events from 9.2% to 12.7% in the STREAM trial

Nov 16, 2026 · Louis Nervegna ♥ 5 Statins

Shared summary of the STREAM randomized trial in adults 70+ on statins for primary prevention. Those told to stop had more heart attacks, strokes or deaths than those who continued, yet the trial formally met its noninferiority margin because that margin allowed a small loss of event-free time. Meeting noninferiority does not show that stopping carried no extra risk, and stopping brought no measurable gain in quality of life, muscle pain or falls.